Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Wet (Neovascular...
Risk adjusted net present value: What is the current valuation of Sandoz Group's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Sandoz Group, with a leading Phase III program in Wet (Neovascular /...
Risk adjusted net present value: What is the current valuation of Amgen's Aflibercept Biosimilar?
Aflibercept Biosimilar is a fusion protein commercialized by Amgen, with a leading Pre-Registration program in Macular Edema. According to Globaldata,...